{
    "title": "GSK shares rally as drugmaker hits back at 'meritless' cancer claims over its heartburn medication amid 3,000 personal injury cases",
    "url": "https://www.dailymail.co.uk/money/article-11105229/GSK-hits-meritless-claims-heartburn-drug.html",
    "date": "2022-08-12",
    "keywords": [
        "gsk",
        "cent",
        "drug",
        "zantac",
        "risk",
        "haleon",
        "share",
        "fund",
        "meritless",
        "treatment",
        "yesterday",
        "injury",
        "litigation",
        "evidence",
        "development",
        "cancer",
        "market",
        "pfizer",
        "trade",
        "investment",
        "account",
        "fee",
        "giant",
        "heartburn",
        "cancerin",
        "reponse",
        "lawsuit",
        "defendant",
        "usit",
        "class",
        "israel",
        "canada",
        "consensusbut",
        "group",
        "consensusboth",
        "food",
        "administration",
        "agency",
        "causal",
        "association",
        "ingredient",
        "factor",
        "business",
        "gdp",
        "june",
        "report",
        "beating",
        "bounce",
        "specialty",
        "industry",
        "momentum",
        "article",
        "drugmaker",
        "sanofi",
        "gskthe",
        "company",
        "weight",
        "conclusion",
        "use",
        "ranitidine",
        "science",
        "trading",
        "friday",
        "meanwhile",
        "july",
        "party",
        "overthecounter",
        "prescription",
        "zantachowever",
        "duo",
        "crosshairspfizer",
        "time",
        "morning",
        "york",
        "capital",
        "isa",
        "month",
        "community",
        "model",
        "affiliate",
        "product",
        "money",
        "commission",
        "editorial",
        "independence",
        "investing",
        "platform"
    ],
    "category": [
        "money"
    ]
}